UBS Group’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-82,016
| Closed | -$3.15M | – | 10290 |
|
|
2023
Q2 | $3.15M | Buy |
82,016
+5,028
| +7% | +$129K | ﹤0.01% | 3059 |
|
|
2023
Q1 | $1.78M | Buy |
76,988
+8,224
| +12% | +$196K | ﹤0.01% | 3552 |
|
|
2022
Q4 | $1.8M | Buy |
68,764
+45,316
| +193% | +$1M | ﹤0.01% | 3488 |
|
|
2022
Q3 | $461K | Buy |
23,448
+9,322
| +66% | +$187K | ﹤0.01% | 4409 |
|
|
2022
Q2 | $248K | Sell |
14,126
-60,288
| -81% | -$946K | ﹤0.01% | 4752 |
|
|
2022
Q1 | $1.22M | Buy |
74,414
+29,388
| +65% | +$400K | ﹤0.01% | 3900 |
|
|
2021
Q4 | $735K | Buy |
45,026
+19,944
| +80% | +$284K | ﹤0.01% | 4659 |
|
|
2021
Q3 | $320K | Buy |
25,082
+23,958
| +2,131% | +$315K | ﹤0.01% | 4998 |
|
|
2021
Q2 | $16K | Buy |
+1,124
| New | +$18K | ﹤0.01% | 7600 |
|
|
2021
Q1 | – | Sell |
-380
| Closed | -$6K | – | 9660 |
|
|
2020
Q4 | $6K | Hold |
380
| – | – | ﹤0.01% | 7794 |
|
|
2020
Q3 | $5K | Sell |
380
-3,453
| -90% | -$46.3K | ﹤0.01% | 7356 |
|
|
2020
Q2 | $44K | Sell |
3,833
-4,798
| -56% | -$66.1K | ﹤0.01% | 5970 |
|
|
2020
Q1 | $118K | Sell |
8,631
-8,596
| -50% | -$102K | ﹤0.01% | 5146 |
|
|
2019
Q4 | $102K | Buy |
17,227
+9,229
| +115% | +$50.2K | ﹤0.01% | 6001 |
|
|
2019
Q3 | $42K | Buy |
7,998
+4,685
| +141% | +$31.1K | ﹤0.01% | 6297 |
|
|
2019
Q2 | $26K | Buy |
3,313
+414
| +14% | +$6.3K | ﹤0.01% | 6447 |
|
|
2019
Q1 | $58K | Buy |
2,899
+1,871
| +182% | +$32.6K | ﹤0.01% | 5446 |
|
|
2018
Q4 | $14K | Sell |
1,028
-27
| -3% | -$539 | ﹤0.01% | 7059 |
|
|
2018
Q3 | $39K | Buy |
1,055
+807
| +325% | +$25.9K | ﹤0.01% | 6356 |
|
|
2018
Q2 | $9K | Sell |
248
-307
| -55% | -$11.8K | ﹤0.01% | 7214 |
|
|
2018
Q1 | $25K | Sell |
555
-2,403
| -81% | -$87.9K | ﹤0.01% | 6262 |
|
|
2017
Q4 | $111K | Sell |
2,958
-3,483
| -54% | -$152K | ﹤0.01% | 5283 |
|
|
2017
Q3 | $343K | Buy |
6,441
+6,177
| +2,340% | +$367K | ﹤0.01% | 4494 |
|
|
2017
Q2 | $15K | Hold |
264
| – | – | ﹤0.01% | 6503 |
|
|
2017
Q1 | $14K | Sell |
264
-1,635
| -86% | -$92.4K | ﹤0.01% | 6420 |
|
|
2016
Q4 | $108K | Buy |
1,899
+1,608
| +553% | +$97.3K | ﹤0.01% | 5236 |
|
|
2016
Q3 | $18K | Sell |
291
-205
| -41% | -$14.5K | ﹤0.01% | 6398 |
|
|
2016
Q2 | $29K | Sell |
496
-1,560
| -76% | -$94.8K | ﹤0.01% | 5968 |
|
|
2016
Q1 | $131K | Buy |
2,056
+1,582
| +334% | +$128K | ﹤0.01% | 4784 |
|
|
2015
Q4 | $67K | Buy |
474
+326
| +220% | +$44.3K | ﹤0.01% | 5561 |
|
|
2015
Q3 | $14K | Buy |
148
+97
| +190% | +$11.6K | ﹤0.01% | 7036 |
|
|
2015
Q2 | $8K | Buy |
+51
| New | +$8.42K | ﹤0.01% | 7631 |
|
UBS Group's KDNY Position: Q3 2023 in Review
UBS Group sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 82,016 shares — an estimated $3.15M sold.
UBS Group first reported a position in KDNY in Q2 2015 and held it in 32 quarters. The position peaked at $3.15M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- UBS Group reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- UBS Group sold 82,016 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $3.15M.
- UBS Group first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 32 quarters.
- UBS Group's Chinook Therapeutics, Inc. Common Stock position peaked at $3.15M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.